IL-17在阿尔茨海默病治疗中的机理机制研究综述
Research Review of the Mechanism of IL-17 in the Treatment of Alzheimer’s Disease
DOI: 10.12677/ns.2025.149209, PDF,    科研立项经费支持
作者: 焦燕琴*, 谢海蝶*, 张建安, 贾云飞, 郑 瑶, 马瑜洁, 张艺馨, 何明颐, 翁佳昇, 王平义#：西藏民族大学医学院/西藏自治区高原胃肠病临床医学研究中心，陕西 咸阳；孙若豪：首都医科大学附属北京天坛医院神经外科，北京；国家神经系统疾病临床医学研究中心，北京
关键词: 阿尔茨海默病；IL-17；作用机制；综述；Alzheimer’s Disease； IL-17； Mechanism of Action； Review
摘要: 阿尔茨海默病作为全球最常见的神经退行性疾病之一，其发病机制复杂且尚未完全阐明，目前仍缺乏能够完全治愈该疾病的有效药物。深入解析其发病机制并开发新型治疗策略，已成为领域内亟待解决的重大科学问题。白细胞介素-17作为关键的促炎细胞因子，近年来越来越多的研究证实其可通过多维度调控网络参与AD的病理进程，并展现出双向调控的特性。然而，目前关于IL-17在AD中多机制协同作用的研究仍缺乏系统性总结。本文聚焦于IL-17在阿尔茨海默病中的具体作用机制展开综述，主要从小胶质细胞、Aβ积累和Tau高度磷酸化、血脑屏障破坏、肠脑轴作用、突触可塑性、靶向治疗等方面对现有研究进行归纳总结，探讨未来研究的方向，以期深化该领域研究，为AD新型治疗策略的开发提供理论依据。
Abstract: Alzheimer’s disease (AD), as one of the most common neurodegenerative diseases globally, has a complex pathogenesis that remains incompletely elucidated. Currently, there is a lack of effective drugs capable of completely curing the disease. In-depth analysis of its pathogenesis and development of novel therapeutic strategies have become major scientific issues that urgently need to be addressed in the field. Interleukin-17 (IL-17), as a key pro-inflammatory cytokine, has been increasingly confirmed in recent years to participate in the pathological process of AD through a multidimensional regulatory network, exhibiting bidirectional regulatory characteristics. However, systematic summaries on the synergistic effects of multiple mechanisms of IL-17 in AD are still lacking. This article focuses on the specific mechanisms of action of IL-17 in AD, mainly summarizing existing research from aspects such as microglia, Aβ accumulation and tau hyperphosphorylation, blood-brain barrier disruption, gut-brain axis function, synaptic plasticity, and targeted therapy, and discusses future research directions, with the aim of deepening research in this field and providing theoretical basis for the development of novel therapeutic strategies for AD.
文章引用：焦燕琴, 谢海蝶, 孙若豪, 张建安, 贾云飞, 郑瑶, 马瑜洁, 张艺馨, 何明颐, 翁佳昇, 王平义. IL-17在阿尔茨海默病治疗中的机理机制研究综述[J]. 护理学, 2025, 14(9): 1576-1582. https://doi.org/10.12677/ns.2025.149209

参考文献

[1] Scheltens, P., De Strooper, B., Kivipelto, M., Holstege, H., Chételat, G., Teunissen, C.E., et al. (2021) Alzheimer’s Disease. The Lancet, 397, 1577-1590. [Google Scholar] [CrossRef] [PubMed]
[2] Mills, K.H.G. (2022) IL-17 and Il-17-Producing Cells in Protection versus Pathology. Nature Reviews Immunology, 23, 38-54. [Google Scholar] [CrossRef] [PubMed]
[3] Chen, J., Jiang, G., Li, Q., Zhou, Z. and Cheng, Q. (2014) Increased Serum Levels of Interleukin-18,-23 and-17 in Chinese Patients with Alzheimer’s Disease. Dementia and Geriatric Cognitive Disorders, 38, 321-329. [Google Scholar] [CrossRef] [PubMed]
[4] Ribeiro, M., Brigas, H.C., Temido-Ferreira, M., Pousinha, P.A., Regen, T., Santa, C., et al. (2019) Meningeal γδ T Cell-Derived IL-17 Controls Synaptic Plasticity and Short-Term Memory. Science Immunology, 4, eaay5199. [Google Scholar] [CrossRef] [PubMed]
[5] Lee, B., Kwon, J., Jeong, Y., Caris, H., Oh, D., Feng, M., et al. (2025) Inflammatory and Anti-Inflammatory Cytokines Bidirectionally Modulate Amygdala Circuits Regulating Anxiety. Cell, 188, 2190-2202.e15. [Google Scholar] [CrossRef] [PubMed]
[6] Lee, Y., Ishikawa, T., Lee, H., Lee, B., Ryu, C., Davila Mejia, I., et al. (2025) Brain-Wide Mapping of Immune Receptors Uncovers a Neuromodulatory Role of IL-17E and the Receptor Il-17RB. Cell, 188, 2203-2217.e17. [Google Scholar] [CrossRef] [PubMed]
[7] Heneka, M.T., Carson, M.J., Khoury, J.E., Landreth, G.E., Brosseron, F., Feinstein, D.L., et al. (2015) Neuroinflammation in Alzheimer’s Disease. The Lancet Neurology, 14, 388-405. [Google Scholar] [CrossRef] [PubMed]
[8] Twarowski, B. and Herbet, M. (2023) Inflammatory Processes in Alzheimer’s Disease—Pathomechanism, Diagnosis and Treatment: A Review. International Journal of Molecular Sciences, 24, Article 6518. [Google Scholar] [CrossRef] [PubMed]
[9] Cao, M., Liu, J., Zhang, X., Wang, Y., Hou, Y., Song, Q., et al. (2023) IL-17A Promotes the Progression of Alzheimer’s Disease in APP/PS1 Mice. Immunity & Ageing, 20, Article No. 74. [Google Scholar] [CrossRef] [PubMed]
[10] Lu, Y., Zhang, P., Xu, F., Zheng, Y. and Zhao, H. (2023) Advances in the Study of IL-17 in Neurological Diseases and Mental Disorders. Frontiers in Neurology, 14, Article 1284304. [Google Scholar] [CrossRef] [PubMed]
[11] Zhang, H., Wei, W., Zhao, M., Ma, L., Jiang, X., Pei, H., et al. (2021) Interaction between Aβ and Tau in the Pathogenesis of Alzheimer’s Disease. International Journal of Biological Sciences, 17, 2181-2192. [Google Scholar] [CrossRef] [PubMed]
[12] Zenaro, E., Pietronigro, E., Bianca, V.D., Piacentino, G., Marongiu, L., Budui, S., et al. (2015) Neutrophils Promote Alzheimer’s Disease-Like Pathology and Cognitive Decline via LFA-1 Integrin. Nature Medicine, 21, 880-886. [Google Scholar] [CrossRef] [PubMed]
[13] Chen, Z., Balachandran, Y.L., Chong, W.P. and Chan, K.W.Y. (2024) Roles of Cytokines in Alzheimer’s Disease. International Journal of Molecular Sciences, 25, Article 5803. [Google Scholar] [CrossRef] [PubMed]
[14] Chen, J., Li, Q., Jiang, G., Liu, J. and Cheng, Q. (2019) IL-18 Induced IL-23/IL-17 Expression Impairs Aβ Clearance in Cultured THP-1 and BV2 Cells. Cytokine, 119, 113-118. [Google Scholar] [CrossRef] [PubMed]
[15] Cristiano, C., Volpicelli, F., Lippiello, P., Buono, B., Raucci, F., Piccolo, M., et al. (2019) Neutralization of IL‐17 Rescues Amyloid‐β‐Induced Neuroinflammation and Memory Impairment. British Journal of Pharmacology, 176, 3544-3557. [Google Scholar] [CrossRef] [PubMed]
[16] Yan, X., Lai, L., Ao, Q., Tian, X. and Zhang, Y. (2022) Interleukin-17a in Alzheimer’s Disease: Recent Advances and Controversies. Current Neuropharmacology, 20, 372-383. [Google Scholar] [CrossRef] [PubMed]
[17] Huppert, J., Closhen, D., Croxford, A., White, R., Kulig, P., Pietrowski, E., et al. (2009) Cellular Mechanisms of IL‐17‐Induced Blood‐Brain Barrier Disruption. The FASEB Journal, 24, 1023-1034. [Google Scholar] [CrossRef] [PubMed]
[18] Kebir, H., Kreymborg, K., Ifergan, I., Dodelet-Devillers, A., Cayrol, R., Bernard, M., et al. (2007) Human TH17 Lymphocytes Promote Blood-Brain Barrier Disruption and Central Nervous System Inflammation. Nature Medicine, 13, 1173-1175. [Google Scholar] [CrossRef] [PubMed]
[19] Siffrin, V., et al. (2010) In Vivo Imaging of Partially Reversible Th17 Cell-Induced Neuronal Dysfunction in the Course of Encephalomyelitis. Immunity, 33, 424-436.
[20] Khan, S., Barve, K.H. and Kumar, M.S. (2020) Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease. Current Neuropharmacology, 18, 1106-1125. [Google Scholar] [CrossRef] [PubMed]
[21] Hao, W., Luo, Q., Tomic, I., Quan, W., Hartmann, T., Menger, M.D., et al. (2024) Modulation of Alzheimer’s Disease Brain Pathology in Mice by Gut Bacterial Depletion: The Role of Il-17a. Gut Microbes, 16, Article ID: 2363014. [Google Scholar] [CrossRef] [PubMed]
[22] Mangina, C.A. and Sokolov, E.N. (2006) Neuronal Plasticity in Memory and Learning Abilities: Theoretical Position and Selective Review. International Journal of Psychophysiology, 60, 203-214. [Google Scholar] [CrossRef] [PubMed]
[23] Zhang, J., Ke, K.F., Liu, Z., Qiu, Y.H. and Peng, Y.P. (2013) Th17 Cell-Mediated Neuroinflammation Is Involved in Neurodegeneration of Ab1-42-Induced Alzheimer’s Disease Model Rats. PLOS ONE, 8, e75786.
[24] Tfilin, M. and Turgeman, G. (2019) Interleukine-17 Administration Modulates Adult Hippocampal Neurogenesis and Improves Spatial Learning in Mice. Journal of Molecular Neuroscience, 69, 254-263. [Google Scholar] [CrossRef] [PubMed]
[25] Brigas, H.C., Ribeiro, M., Coelho, J.E., Gomes, R., Gomez-Murcia, V., Carvalho, K., et al. (2021) IL-17 Triggers the Onset of Cognitive and Synaptic Deficits in Early Stages of Alzheimer’s Disease. Cell Reports, 36, Article ID: 109574. [Google Scholar] [CrossRef] [PubMed]
[26] Li, J., Casanova, J. and Puel, A. (2018) Mucocutaneous IL-17 Immunity in Mice and Humans: Host Defense vs. Excessive Inflammation. Mucosal Immunology, 11, 581-589. [Google Scholar] [CrossRef] [PubMed]
[27] Langley, R.G., Elewski, B.E., Lebwohl, M., Reich, K., Griffiths, C.E.M., Papp, K., et al. (2014) Secukinumab in Plaque Psoriasis—Results of Two Phase 3 Trials. New England Journal of Medicine, 371, 326-338. [Google Scholar] [CrossRef] [PubMed]
[28] Wu, S., Xu, Y., Yang, L., Guo, L. and Jiang, X. (2023) Short-term Risk and Long-Term Incidence Rate of Infection and Malignancy with IL-17 and IL-23 Inhibitors in Adult Patients with Psoriasis and Psoriatic Arthritis: A Systematic Review and Meta-Analysis. Frontiers in Immunology, 14, Article 1294416. [Google Scholar] [CrossRef] [PubMed]

为你推荐